Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML

Recruiting

Phase 1

Phase 2

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML

Sponsor:

Sutro Biopharma, Inc.

Code:

NCT06679582

Conditions

Acute Myeloid Leukemia (AML)

Eligibility Criteria

Sex: All

Age: 1 - 12

Healthy Volunteers: Not accepted

Interventions

Luveltamab tazevibulin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information